After it recorded an initial failure in a phase II randomized trial (n = 87) when administered in patients with pre-treated advanced-stage NSCLC, recently it came forth from the phase III NEPTUNE trial (NCT02542293, phase III, randomized, 953 participants) that a combination of Tremelimumab plus Imfinzi (Durvalumab, anti-PD-L1 antibody) performed no better than standard chemotherapy at extending the survival of people with metastatic NSCLC [164]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.